ENRICH-AF
A randomised clinical trial investigating if people with atrial fibrillation (irregular heartbeat), who have had a brain haemorrhage actually benefit from starting anticoagulant drugs.
Condition(s)
- Stroke due to brain haemorrhage
Project type
- Clinical drug trial
About the project
ENRICH-AF stands for EdoxabaN for IntraCranial Haemorrhage survivors with Atrial Fibrillation.
Bleeding within the skull, also known as brain haemorrhage, affects 3 million people in the world each year.
One in five people who survive brain haemorrhage have an irregular heart rhythm called 'atrial fibrillation', which puts them at risk of stroke and other blood clots.
Blood-thinning medicines, known as 'anticoagulant' drugs, are used in everyday clinical practice to protect people with atrial fibrillation from developing blood clots. However, as these drugs also increase the risk of bleeding, it is not known whether they should be prescribed to people who have had a brain haemorrhage.
ENRICH-AF is a randomised clinical trial to produce reliable information about whether people with atrial fibrillation who have had a brain haemorrhage benefit from starting anticoagulant drugs.
More information
Population Health Research Institute
ClinicalTrials.gov identifier: NCT03950076
Photo by @drugwatcher?utm_source=unsplash&utm_medium=referral&utm_content=creditCopyText">Derek Finch on Unsplash
Publication(s)
Status
Contact
Eligibility criteria
Recruitment criteria are correct at the time of publishing.
People with atrial fibrillation who have had a brain haemorrhage.